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Abstract.  – OBJECTIVE: To evaluate the diag-
nostic accuracy of the Food and Drug Adminis-
tration Emergency Use Authorization (FDA-EUA) 
authorized point-of-care tests (POCTs) for the 
detection of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).
MATERIALS AND METHODS: A systemat-
ic literature search was conducted using the 
PubMed, Embase, and Web of Science databas-
es for articles published till August 10, 2020. We 
included studies providing information regard-
ing diagnostic test accuracy of FDA-EUA POCTs 
for SARS-CoV-2 detection. The methodologic 
quality was assessed using the Quality Assess-
ment of Diagnostic Accuracy Studies-2 tool. The 
review protocol is registered in the Internation-
al Prospective Register of Systematic Reviews 
(protocol number CRD42020202248).
RESULTS: We included 26 studies describing 
a total of 3242 samples. The summary sensitivity 
and specificity were 0.94 [95% confidence interval 
(CI): 0.88-0.97] and 1.00 (95% CI: 0.99-1.00), respec-
tively. The area under the summary receiver oper-
ating characteristic curve was 1.00 (95% CI: 0.99-
1.00). A pooled analysis based on the index test 
revealed a summary sensitivity and specificity of 
Cepheid Xpert Xpress SARS-CoV-2 [0.99 (95% CI: 
0.97-1.00) and 0.99 (95% CI: 0.94-1.00, respective-
ly)] and ID NOW COVID-19 [0.78 (95% CI: 0.74-0.82) 
and 1.00 (95% CI: 0.98-1.00), respectively].
CONCLUSIONS: FDA-EUA POCTs, especially 
molecular assays, have high sensitivity, speci-
ficity, and overall diagnostic accuracy for detect-
ing SARS-CoV-2. If approved, FDA-EUA POCTs 
can provide a rapid and practical way to identify 
infected individuals early on and help to limit the 
strain on the healthcare system. However, more 
high-quality clinical data are required to support 
our results.
Key Words:
COVID-19, SARS-CoV-2, Diagnosis, Point-of-care 
test, Rapid test.
Introduction
Coronavirus disease 2019 (COVID-19), 
caused by the Severe Acute Respiratory Syn-
drome Coronavirus 2 (SARS-CoV-2), was de-
clared a public health emergency of internation-
al concern on January 30, 20201, and declared 
a pandemic on March 11, 2020, by the World 
Health Organization (WHO)2. Currently, the 
gold standard for identification of SARS-CoV-2 
is the Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) assay3; however, RT-PCR 
requires trained laboratory staff and expensive 
equipment and has a long turnaround time4.
Given the high global burden of COVID-19, 
the need to develop point-of-care tests (POCTs) 
has been increasing. POCTs are rapid diagnos-
tic tests that can be performed at the site of sam-
ple collection, such as the bedside, urgent care 
centers, and emergency departments, without a 
time-consuming laboratory process5-8. The ra-
pidity and convenience of POCTs not only can 
help fast epidemiological tracing with quaran-
tine of individuals infected with SARS-CoV-2 
but also reduce the financial cost and strain 
on the healthcare system during the pandem-
ic9-11. The U.S. Food and Drug Administration 
(FDA) issued Emergency Use Authorizations 
(EUAs) to several manufacturers of POCTs for 
SARS-CoV-2 diagnosis12. Currently, six Clin-
ical Laboratory Improvement Amendment of 
1988 (CLIA)-waived POCTs are EUA approved 
for SARS-CoV-2 testing. The species and char-
acteristics of FDA-EUA POCTs are shown in 
Table I. In the present study, we aimed to evalu-
ate the overall diagnostic accuracy of currently 
available FDA-EUA POCTs for the detection of 
SARS-CoV-2.
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Materials and Methods
The methods and results of this review are 
presented according to the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses 
(PRISMA) statement13. The review protocol is 
registered in the International Prospective Regis-
ter of Systematic Reviews (PROSPERO) (proto-
col number CRD42020202248).
Search Strategy
We searched PubMed, EMBASE, and Web 
of Science databases using the following terms: 
(“COVID-19” OR “severe acute respiratory syn-
drome coronavirus 2” OR “SARS-CoV-2” OR 
“coronavirus disease-19”) AND (“emergency 
use authorization” OR “FDA-EUA”) AND (“di-
agnosis” OR “detection” OR “point-of-care test-
ing” OR “rapid test”). We limited the articles to 
those that were published in English, without any 
date restrictions. The most recent search was per-
formed on August 10, 2020.
Eligibility Criteria
Studies were considered eligible if they as-
sessed the accuracy of FDA-POCTs for the di-
agnosis of SARS-CoV-2 in human respiratory 
specimens. Studies using RT-PCR or real-time 
RT-PCR as reference standards were eligible 
for inclusion in the current study. Reviews, 
editorials, expert opinions, and animal exper-
iments were excluded. Reports that presented 
duplicate data and studies with insufficient data 
to construct 2 × 2 contingency tables were also 
excluded.
Study Selection and Data Extraction
Three authors (SHY, SY, and HC) independent-
ly assessed the studies retrieved by the search, for 
eligibility. If there was disagreement between the 
reviewers’ assessments, consensus was reached 
through discussion. Author names, publication 
year, country of origin, study period, age of study 
participants (children were defined as ≤ 18 years 
of age), type of specimen, type of index test, 
brand name of the index test, reference standard, 
number of samples tested, and the values of true 
positive, false positive, true negative, and false 
negative were extracted. If studies consisted of 
multiple groups, each group was considered as an 
individual study. If articles provided insufficient 
data to construct the 2 × 2 table, we attempted 
to contact the corresponding authors via email to 
obtain more information.
Table I. The six commercial SARS–CoV-2 diagnostic assays given an EUA from the FDA for use outside the clinical laboratory 
environment as of August 10, 2020.
Date EUA     Time
Issued Test Name Manufacturer Test Type Specific Test assay to result Target
03/20/2020 Xpert Xpress Cepheid Molecular  Real-time RT-PCR ~45 min Envelope (E)
 SARS-CoV-2  (NAAT)   gene and   
      nucleocapsid (N)
      gene (N2 region)
03/23/2020 Accula  Mesa Biotech Molecular RT-PCR + lateral ~30 min Nucleocapsid
 SARS-Cov-2 Inc. (NAAT) flow assay  protein (N) gene
03/27/2020 ID NOW  Abbott Molecular Isothermal nucleic ~13 min RdRP gene
 COVID-19 Diagnostics (NAAT) acid amplification
  Scarborough, Inc.  assay  
05/08/2020 Sofia SARS  Quidel Antigen Immunofluorescence-based  Nucleocapsid
 Antigen FIA Corporation  lateral flow assay ~15 min protein antigen
06/10/2020 Cue COVID-19 Cue Health Inc. Molecular  Isothermal nucleic acid  Nucleocapsid
   (NAAT) amplification assay ~25 min protein (N) gene
07/02/2020 BD Veritor  Becton, Antigen Chromatographic  ~15 min Nucleocapsid
 System for  Dickinson and  digital immunoassay   protein antigen
 Rapid Company  
 Detection of   
 SARS-CoV-2
EUA = emergency use authorization; FDA = the U.S. Food and Drug Administration; NAAT = nucleic acid amplification test; 
RT-PCR = reverse transcription polymerase chain reaction; SARS–CoV-2 = severe acute respiratory syndrome coronavirus 2.
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Assessment of Methodologic Quality
The methodological quality of the selected 
studies was independently assessed using Qual-
ity Assessment of Diagnostic Accuracy studies-2 
(QUADAS-2)14 by two reviewers (SHY and SE). 
Any discrepancies were arbitrated by discussion.
Statistical Analysis
The pooled sensitivity, specificity, positive 
likelihood ratio (PLR), negative likelihood ratio 
(NLR), diagnostic odds ratio (DOR), and corre-
sponding 95% confidence intervals (CIs) of the 
corresponding index test were calculated using 
the accuracy data (true positive, false positive, 
false negative, and true negative) extracted from 
each eligible study. We used summary receiver 
operating characteristic (SROC) curves to calcu-
late the area under the curve.
Statistical heterogeneity was evaluated from 
the forest plots of the studies’ estimates, using 
the Cochran’s Q test (p<0.05, significant) and 
I2 statistic (I2>50%, significant) with 95% CIs. 
In the presence of significant heterogeneity, we 
conducted subgroup analysis and univariate 
meta-regression analysis to assess heterogene-
ity using the following as covariates with 95% 
CIs: index test (Xpert vs. ID NOW), sample size 
(<100 vs. ≥100), age of participants (adults vs. 
adults and children), type of specimen (nasal 
or nasopharyngeal specimen; nasopharyngeal 
swab [NPS]/nasal swab/nasal or nasopharyn-
geal samples vs. other specimens; oropharyn-
geal swab [OPS] or tracheal aspirate [TA]), 
country (USA vs. other country), and type of 
transport medium (viral transport medium 
[VTM] vs. others [universal transport medium 
(UTM), saline, either UTM or VTM]).
Publication bias was assessed using the 
Deeks’ funnel plot, and p<0.1 indicated the 
presence of publication bias. All statistical anal-
yses were performed using STATA software, 
Version 16.1 (StataCorp, College Station, TX, 
USA) with the MIDAS module and MedCalc 
Statistical Software version 19.5.3 (MedCalc 
Software, Ostend, Belgium). p-values<0.05 
were considered statistically significant.
Results
Study Selection and Article 
Characteristics
The search led to 100 results; after removing 
the duplicates, the remaining 68 abstracts were 
screened; 46 articles were excluded, resulting in 
22 articles included for the full-text review. Of 
these, six studies were excluded due to insuffi-
cient data, to construct a 2 × 2 contingency ta-
ble. One study was excluded because it used stool 
specimens. Therefore, 26 articles comprising 
3242 samples were finally included in the system-
atic review and meta-analysis11,15-27 (Figure 1).
The main characteristics of the included arti-
cles are summarized in Table II. The number of 
patients in the studies ranged from 10 to 524. The 
studies were conducted between February and 
May 2020, and most studies were conducted in 
the USA11,16,17,19-27. All the FDA-EUA POCTs in-
cluded in this review are molecular assays, and 
the test samples used were respiratory tract spec-
imens. Thirteen studies (50%) used Xpert Xpress 
SARS-CoV-2 (Xpert; Cepheid, Sunnyvale, CA, 
USA)15,18-20,23-25,27, 12 studies (46.2%) used ID 
NOW COVID-19 (ID NOW; Abbott Diagnos-
tics, Inc., Scarborough, ME, USA)11,16,21,22,24,26,27, 
and 1 study (3.8%) used the Accula SARS-CoV-2 
POCT (Accula; Mesa Biotech Inc, 2020)17 as the 
index assay. All studies used real-time RT-PCR 
as the reference standard. Most of the studies 
(n=18)11,15,17,19,20,22,24-27 used NPS specimens. The 
age of the participants was not specified in about 
half of the studies (11/26, 42.3%)11,16,19,21,23,25,26; five 
studies (19.2%)15,20 included adults only, and ten 
studies (38.5%)17,18,20,22,24,27 included both adults 
and children.
Quality Assessment
Quality was assessed using QUADAS-2 (Fig-
ure 2). For the risk of bias, regarding the patient 
selection domain, 46.2% of the studies were 
scored as having “high” risk of bias because they 
did not report the methods used for the enrollment 
(whether consecutive or random), or the exclusion 
criteria. Regarding the index test domain, half of 
the studies (50.0%) were scored as “unclear” risk 
of bias because the authors did not clarify wheth-
er the index test results were identified without 
the knowledge of the results of the reference stan-
dard. However, if the index test was an RT-PCR, 
the studies were judged to be at low risk of bias 
(50.0%), because RT-PCR was regarded as an 
objective method. Regarding the reference stan-
dard domain, all the studies were considered to 
be at “low” risk of bias because they all used the 
real-time RT-PCR as the reference standard. Re-
garding the flow and timing domain, 15 studies 
(57.7%) had an unclear risk of bias because the 
interval between the index test and the reference 
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Year, Author Country Study periods Age Specimen Media Index test assay
Reference 
standard TP FP FN TN
2020 Cradic et al11 USA NA NA NPS UVT ID NOW COVID-19 Real-time RT-PCR 12 0 1 169
2020 Cradic et al11 USA NA NA OPS Dry OPS ID NOW COVID-19 Real-time RT-PCR 12 0 1 169
2020 Cradic et al11 USA NA NA NS Dry NS ID NOW COVID-19 Real-time RT-PCR 12 0 1 169
2020 Goldenberger et al15 Switzerland Mar 2020* adults NPS UTM and ESwab™ Xpert Xpress SARS-CoV-2 Real-time RT-PCR 10 0 0 9
2020 Harrington et al16 USA NA NA NS VTM ID NOW COVID-19 Real-time RT-PCR 139 2 47 336




saline Accula SARS-CoV-2 POCT Real-time RT-PCR 34 0 16 50
2020 Hou et al18 China Feb–Apr, 2020 adults and children¶ OPS NA Xpert Xpress SARS-CoV-2 Real-time RT-PCR 147 5 6 127
2020 Lieberman et al19 USA NA NA** NPS VTM Xpert Xpress SARS-CoV-2 Real-time RT-PCR 13 0 0 13
2020 Loeffelholz et al20 USA Mar 1–Apr 2, 2020 adults NPS VTM Xpert Xpress SARS-CoV-2
†† Real-time RT-PCR 12 0 1 75
2020 Loeffelholz et al20 FR and USA
Mar 1–Apr 2, 
2020 adults NPS VTM Xpert Xpress SARS-CoV-2
†† Real-time RT-PCR 60 0 0 69







Saline† Xpert Xpress SARS-CoV-2
†† Real-time RT-PCR 74 2 0 23
2020 Loeffelholz et al20 UK Mar 1–Apr 2, 2020 adults
NPS, NPS/
OPS VTM Xpert Xpress SARS-CoV-2
†† Real-time RT-PCR 30 9 0 26
2020 Loeffelholz et al20 IT Mar 1–Apr 2, 2020
adults and 
children NPS VTM Xpert Xpress SARS-CoV-2
†† Real-time RT-PCR 35 0 0 44
2020 Loeffelholz et al20 USA Mar 1–Apr 2, 2020 adults NPS VTM Xpert Xpress SARS-CoV-2
†† Real-time RT-PCR 8 0 0 10




VTM ID NOW COVID-19 Real-time RT-PCR 33 0 13 15
2020 Moore et al22 USA Mar 27–Apr 9, 2020
adults and 
children NPS VTM ID NOW COVID-19 Real-time RT-PCR 94
‡ 0 23 79
2020 Moore et al22 USA Mar 27–Apr 9, 2020
adults and 
children NPS VTM ID NOW COVID-19 Real-time RT-PCR 94
‡ 0 31 73
Table II. Characteristics of studies included in the meta-analysis.
Table continued
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Table II. (Continued). Characteristics of studies included in the meta-analysis.
USA = the United States of America; NA = not available; UVT = universal viral transport medium; RT-PCR = reverse transcription polymerase chain reaction; NPS = nasopharyngeal 
swab; OPS = oropharyngeal swab; NPS/OPS = combined NPS-OPS in the same transport vial; NS = nasal swab; VTM = viral transport medium; UTM = universal transport media; 
UK = the United Kingdom; FR = France; IT = Italy; TA = tracheal aspirates; *Collected within a week during the first wave of the 2020 pandemic in Basel, Switzerland ¶ 77.2% of the 
patients were ≤ 65 years old, and 22.8% of patients were> 65 years old. **Overwhelmingly adult. ††Research use only (RUO)-labeled Xpert kits were used. The RUO version of Xpert 
allows users to see amplification curves and PCR cycle threshold values for all three targets; the envelope (E), nucleocapsid (N2), and RNA-dependent RNA polymerase (RdRp) genes.
†Tracheal aspirates were diluted with saline. ‡Invalid and inconclusive results were excluded. §Performed at the Stanford Healthcare Virology Laboratory that serves both adult and 
pediatric tertiary care hospitals.
Year, Author Country Study periods Age Specimen Media Index test assay
Reference 
standard TP FP FN TN





NA Xpert Xpress SARS-CoV-2 Real-time RT-PCR 42 1 0 60




UTM ID NOW COVID-19 Real-time RT-PCR 65 0 23 25




UTM Xpert Xpress SARS-CoV-2 Real-time RT-PCR 87 2 1 23
2020 Stevens et al25 USA Mar 31–Apr 7, 2020 NA
§ NPS VTM Xpert Xpress SARS-CoV-2 Real-time RT-PCR 53 0 1 50
2020 Thwe et al26 USA Apr–May, 2020 NA NPS Dry NPS ID NOW COVID-19 Real-time RT-PCR 6 0 4 119
2020 Thwe et al26 USA Apr–May, 2020 NA NPS Dry NPS ID NOW COVID-19 Real-time RT-PCR 1 0 1 8
2020 Thwe et al26 USA Apr–May, 2020 NA NPS Dry NPS ID NOW COVID-19 Real-time RT-PCR 1 0 1 20
2020 Zhen et al27 USA Mar–Apr, 2020 adults and children NPS UTM Xpert Xpress SARS-CoV-2 Real-time RT-PCR 57 0 1 50
2020 Zhen et al27 USA Mar–Apr, 2020 adults and children NPS UTM ID NOW COVID-19 Real-time RT-PCR 50 0 7 50
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test was not provided. Regarding applicability, we 
scored as low concern for all the studies in all the 
three domains.
Diagnostic Performance of Emergency 
Use Authorization Point-Of-Care Tests
The sensitivities and specificities of the in-
dividual studies ranged from 50% to 100% and 
74% to 100%, respectively. As shown in Figure 
3, the summary sensitivity and specificity were 
0.94 (95% CI: 0.88-0.97) and 1.00 (95% CI: 0.99-
1.00), respectively. The summary PLR and NLR 
were 483.6 (95% CI: 68.2-3429.7) and 0.06 (95% 
CI: 0.03-0.12), respectively. The DOR was 8490 
(95% CI: 1243-57971). The area under the SROC 
curve was 1.00 (95% CI: 0.99-1.00) (Figure 4). 
The Higgins I2 statistics demonstrated substantial 
heterogeneity in terms of both the sensitivity (I2 = 
94%) and specificity (I2 = 95%). Publication bias 
was not detected according to Deeks’ funnel plot 
(p=0.92) (Figure 5).
Heterogeneity Exploration
Potential sources of heterogeneity were investigat-
ed using meta-regression (Table III). Among the sev-
eral covariates, index type, age, type of specimen, and 
transport medium were significant factors affecting 
heterogeneity in the joint model. When comparing 
the sensitivity and specificity estimates with the co-
variates, the pooled sensitivity was significantly high-
er in studies conducted on adults only than studies 
conducted on adults and children. The pooled speci-
ficity was significantly higher in studies conducted on 
nasal or nasopharyngeal specimen (p<0.01).
Subgroup Analysis
We performed subgroup analysis separately 
for each index test because the principle of each 
Figure 1. Flow diagram of the study selection.
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assay is different: Xpert uses RT-PCR, and ID 
NOW uses an isothermal nucleic acid amplifica-
tion method.
Diagnostic Performance of Xpert Xpress 
SARS-CoV-2
The sensitivities and specificities of the indi-
vidual studies ranged from 92% to 100% and 74% 
to 100%, respectively (Figure 6). The summary 
sensitivity was 0.99 (95% CI: 0.97-1.00) and the 
summary specificity was 0.99 (95% CI: 0.94-
1.00) (Figure 6). The summary PLR and NLR 
were 100.1 (95% CI: 17.4-575.4) and 0.01 (95% CI: 
0.00-0.03), respectively. The DOR was 8538 (95% 
CI: 1087- 67079). The area under the SROC curve 
was 1.00 (95% CI: 0.99-1.00) (Figure 7). Publi-
Figure 2. Quality assessment using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) of the included studies.










Xpert 13 0.98 [0.98 - 0.99]
0.61   
0.99 [0.97 - 1.00]   
0.88 49.64 <0.01
ID NOW 12 0.78 [0.74 - 0.82] 1.00 [1.00 - 1.00]   
Age
Adults 5 1.00 [0.99 - 1.00]   
<0.01
1.00 [0.98 - 1.00]   
<0.01 71.97 <0.01Adults and 





22 0.93 [0.87 - 0.98]   
0.14   
1.00 [1.00 - 1.00]
<0.01 7.59      <0.05
Others¶ 4 0.99 [0.96 - 1.00]   0.96 [0.89 - 1.00]
Media
VTM 11 0.96 [0.91 - 1.00]
0.85   
1.00 [0.99 - 1.00]
<0.01 43.78  <0.01
Others 8 0.96 [0.90 - 1.00] 1.00 [0.99 - 1.00]
Size (n)
≥100 16 0.92 [0.86 - 0.99]
0.12
1.00 [1.00 - 1.00]
<0.01 1.69      0.43     
<100 10 0.97 [0.93 - 1.00] 1.00 [0.99 - 1.00]
Country
USA 22 0.92 [0.87 - 0.98]   
0.13
1.00 [1.00 - 1.00]   
<0.01 3.57      0.17     Other 
countries 4 0.99 [0.97 - 1.00] 1.00 [0.98 - 1.00] 
Table III. Stratified meta-regression analyses.
CI = confidence interval; ID NOW = ID Now COVID-19; LRT = likelihood-ratio test; VTM = viral transport medium; Xpert = 
Xpert Xpress SARS-CoV-2; USA = the United States of America. ¶ Oropharyngeal swab, tracheal aspirate, or mixed (e.g., naso-
pharyngeal and oropharyngeal) samples.
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cation bias was not detected using Deeks’ funnel 
plot (p=0.70) (Figure 8). Sensitivity and speci-
ficity showed I2>50%, indicating considerable 
heterogeneity. The age of the study participants 
(p<0.05), type of specimen (p<0.05), and trans-
port medium (p<0.01) were significant covariates 
affecting heterogeneity in the meta-regression 
analysis. When comparing sensitivity and speci-
ficity estimates with covariates, the pooled speci-
ficity was higher in studies with nasal or nasopha-
ryngeal specimen (p<0.05), adults only (p<0.01), 
and using VTM (p<0.01) (Table IV).
Diagnostic Performance of ID NOW 
COVID-19
The sensitivities and specificities of the indi-
vidual studies ranged from 50% to 92% and 99% 
to 100%, respectively (Figure 9). The summary 
sensitivity was 0.78 (95% CI: 0.74-0.82) and sum-
Figure 3. Coupled forest plots of summary sensitivity and specificity. Numbers are pooled estimates with 95% confidence 
intervals (CIs) in parentheses. Corresponding heterogeneity statistics are provided at the bottom-right corners. Horizontal 
lines indicate 95% CIs.
Figure 4. Summary receiver operating characteristic 
curve of diagnostic performance of point-of-care tests for 
the SARS-CoV-2 detection.
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CI: 0.18-0.26), respectively. The DOR was 4551 
(95% CI: 162-127532). The area under the SROC 
curve was 0.89 (95% CI: 0.86-0.91) (Figure 10). 
The Higgins I2 statistics demonstrated that there 
was low heterogeneity in terms of either the sen-
sitivity (I2=27%) or specificity (I2=0%); thus, we 
did not perform meta-regression analysis. Deeks’ 
funnel plot demonstrated no significant publica-
tion bias (p=0.64) (Figure 11).
Diagnostic Performance of Accula 
SARS-CoV-2 Test
There was only one study that used the Accu-
la SARS-CoV-2 test as the index test17; therefore, 
subgroup analysis could not be performed. The 
study showed that the sensitivity and specificity 
of Accula SARS-CoV-2 were 0.68 (95% CI: 0.53-
0.81) and 1.00 (95% CI: 0.93-1.00), respectively. 
The NLR and the accuracy were 0.32 (95% CI: 
0.21-0.48) and 0.84 (95% CI: 0.75-0.91), respec-
tively.
Figure 5. Deeks’ funnel plot asymmetry test. Likelihood 
of publication bias was low with p value of 0.92 for slope 
coefficient. ESS = effective sample size.
Table IV. Stratified meta-regression analyses of studies using Xpert Xpress SARS-CoV-2 as an index test.
CI = confidence interval; LRT = likelihood-ratio test; VTM = viral transport medium; USA = the United States of America. ¶ 
Oropharyngeal swab, tracheal aspirate, or mixed (e.g., nasopharyngeal and oropharyngeal) samples.




















10 0.99 [0.98 - 1.00]
0.70
0.99 [0.99 - 1.00]
<0.05 10.18 <0.05
Others¶ 3 0.99 [0.96 - 1.00] 0.90 [0.80 - 1.00]
Media
VTM 7 0.99 [0.98 - 1.00]
0.51
1.00 [1.00 - 1.00]
<0.01 22.50 <0.01
Others 4 0.99 [0.98 - 1.00] 0.99 [0.96 - 1.00]
Size (n)




<100 7 1.00 [0.98-1.00] 0.99 [0.96-1.00]
Country
USA 9 0.99 [0.98 - 1.00]
0.66
0.99 [0.96 - 1.00]
0.19 1.58 0.45
Other countries 4 0.98 [0.96 - 1.00] 1.00 [0.99 - 1.00]
mary specificity was 1.00 (95% CI: 0.98-1.00) 
(Figure 9). The summary PLR and NLR were 
1005.4 (95% CI: 37.6-26906.6) and 0.22 (95% 
S.H. Yoon, S. Yang, H. Cho, S. Eun, C.M. Koo, M.K. Kim
512
Discussion
The timely and accurate confirmation of SARS-
CoV-2 infection is critical to contain the spread of 
infection and reduce mortality27. Approximately, 
80-85% of those affected are asymptomatic or have 
mild symptoms, but some people develop severe dis-
ease, requiring mechanical ventilation and intensive 
care, and sometimes the disease can be fatal. Those 
at risk of severe illness include older adults; people 
with pre-existing medical conditions such as cardio-
vascular disease, cancer, and immune deficiencies; 
and people living in a nursing home6,28-31. For this 
reason, having a fast, convenient, and highly acces-
sible method of laboratory diagnosis is important 
for infection control and appropriate management of 
those at risk of severe illness11,27.
In this meta-analysis, FDA-EUA POCTs for the 
detection of SARS-CoV-2, specifically molecular 
assays, showed high overall sensitivity (0.94), 
specificity (1.0), and accuracy (1.0) for diagnos-
ing SAS-CoV-2 infection. The overall sensitivity 
Figure 6. Coupled forest plots of the summary sensitivity and specificity of Xpert Xpress SARS-CoV-2. Numbers are pooled 
estimates with 95% confidence intervals (CIs) in parentheses. Corresponding heterogeneity statistics are provided at the bot-
tom-right corners. Horizontal lines indicate 95% CIs.
Figure 7. Summary receiver operating characteristic curve 
of the diagnostic performance of Xpert Xpress SARS-
CoV-2 for SARS-CoV-2 detection.
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varied according to the index test: Xpert showed 
high sensitivity (0.99) and specificity (0.99) with 
a very high diagnostic accuracy (1.0). Xpert test 
uses RT-PCR and detects the pan-sarbecovirus E 
gene and the N2 region of the N gene of SARS-
CoV-2 using an NPS, nasal wash, or nasal aspirate 
specimen; it takes less than 45 minutes to obtain 
a result32. ID NOW test uses isothermal nucleic 
acid amplification of the RNA-dependent RNA 
polymerase (RdRP) gene of SARS-CoV-2 using a 
nasal swab, NPS, or throat swab specimen; results 
are available in less than 13 minutes33. However, 
ID NOW has a lower sensitivity and diagnostic 
accuracy than the Xpert test (0.78 vs. 0.99 and 
0.89 vs. 1.0, respectively). In addition, Xpert can 
be run on random-access platforms with a high-
er throughput, but the ID NOW platform can run 
only a single specimen at once24. However, both 
tests displayed a similar high specificity for the 
detection of SARS-CoV-2.
Figure 8. Deeks’ funnel plot asymmetry test for 
studies of Xpert Xpress SARS-CoV-2. Likelihood 
of publication bias was low with a p value of 0.70 for 
the slope coefficient. ESS = effective sample size.
Figure 9. Coupled forest plots of the summary sensitivity and specificity of ID NOW COVID-19. Numbers are pooled 
estimates with 95% confidence intervals (CIs) in parentheses. Corresponding heterogeneity statistics are provided at the bot-
tom-right corners. Horizontal lines indicate 95% CIs.
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There were two head-to-head studies24,27 that 
compared Xpert and ID NOW test to a RT-PCR. 
Smithgall et al24 reported that the overall positive 
percent agreement was 98.9% and 73.9%, and 
the negative percent agreement 92.0% and 100% 
compared to Roche cobas SARS-CoV-2 assay for 
Xpert and ID NOW, respectively. However, at low 
viral concentrations (cycle threshold values>30), 
the positive percent agreement was reduced to 
34.3% for ID NOW, and it was slightly reduced 
to 97.1% for Xpert. The researchers suspected 
that this was because the specimens for ID NOW 
testing were collected in VTM or UTM, which 
may lead to low-level positivity and false-neg-
ative results24. The EUA for ID NOW has been 
updated to remove the use of nasal swab, NPS, or 
throat swabs eluted in VTM33 as specimen types. 
Another study27 reported a positive percent agree-
ment of 98.3% and 87.7% for Xpert and ID NOW, 
respectively, and negative percent agreement was 
100% for both Xpert and ID NOW, compared to 
the reference standard (Hologic Panther Fusion 
SARS-CoV-2 assay).
Regarding specimen types, meta-regression 
analysis showed significantly higher specificity 
for nasal or nasopharyngeal specimens than for 
Figure 10. Summary receiver operating character-
istic curve of the diagnostic performance of ID NOW 
COVID-19 for SARS-CoV-2 detection.
Figure 11. Deeks’ funnel plot asymmetry test for 
studies of ID NOW COVID-19. Likelihood of publi-
cation bias was low with a p value of 0.64 for the slope 
coefficient. ESS = effective sample size.
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other types of respiratory specimens such as OPS, 
TA, and mixed samples (1.0 vs. 0.96; p<0.01). The 
overall sensitivity of nasal or nasopharyngeal 
specimens was lower than that of other types of 
respiratory specimens, but this result was not 
statistically significant (0.93 vs. 0.99; p =0.14). 
Previous studies34-36 have reported that NPS or 
nasal swab showed higher sensitivity and viral 
loads than OPS. However, Wölfel et al37 found 
no discernible differences in the viral loads or 
sensitivity between NPS and OPS in the clinical 
courses of nine hospitalized patients admitted 
for COVID-19. Furthermore, viral loads were 
higher in lower respiratory tract samples than in 
upper respiratory tract samples of COVID-19 pa-
tients38,39, but this could not be evaluated in our 
review because a limited number of TA samples 
were tested. Our findings suggest that nasal or 
nasopharyngeal specimens are more suitable for 
point-of-care testing, but there are still limitations 
since comparisons according to the specimen 
types were not performed in most of the studies.
Our study also demonstrated that the sensitivi-
ty of FDA-EUA POCTs was higher in studies con-
ducted on adults only than in studies conducted 
on both adults and children (1.00 vs. 0.93; p<0.01). 
This finding suggests that the sensitivity of POCTs 
might be lower in children. Jones et al40 analyzed 
RT-PCR data from over 3,000 SARS-CoV-2-pos-
itive patients in Germany and found that the viral 
detection rate increased with age and reached a 
plateau in middle-aged adults. On the contrary, 
another study41 found that among 145 people with 
mild to moderate illness who tested positive for 
SARS-CoV-2 within 1 week of symptom onset, 
children younger than 5 years of age had higher 
viral nucleic acid in their nasopharynx than older 
children and adults. Nevertheless, clinical studies 
focusing on the difference in sensitivity and spec-
ificity of POCTs in children compared with adults 
are still limited.
The sensitivity and specificity were similar be-
tween samples collected in VTM and other me-
dia, such as saline and UTM; however, the type 
of transport medium was a statistically significant 
source of the heterogeneity in our joint model. 
Garnett et al42 recently compared the diagnostic 
performance of samples collected in Dulbec-
co’s Modified Eagle’s Medium (DMEM), phos-
phate-buffered saline (PBS), 0.9% normal saline, 
and 100% ethanol, with VTM as the transport 
medium, for the preservation and recovery of vi-
ral RNA over a 72-hour period. They concluded 
that all media, except the 0.9% saline, were sim-
ilarly efficacious in terms of preserving SARS-
CoV-2 RNA for extraction and detection42.
POCTs for SARS-CoV-2 antibodies are avail-
able; however, their use for clinical purposes is 
questionable. A recently published meta-analy-
sis regarding rapid serologic diagnostic tests for 
SARS-CoV-2 antibodies showed a pooled sensi-
tivity of 0.65 (95% CI: 0.55-0.74) and specificity 
of 0.98 (95% CI: 0.96-0.99), which are lower than 
the results of the molecular assays for SARS-
CoV-2 RNA detection in our review43. Another 
meta-analysis also demonstrated higher accuracy 
for SARS-CoV-2 detection using antigen tests and 
molecular assays than serologic assays: the pooled 
sensitivity and specificity of tests using the detec-
tion of SARS-CoV-2 IgM antibodies compared to 
antigen and molecular assays in NPS/OPS swabs 
were 0.82 (95% CI: 0.76-0.87) vs. 0.97 (95% CI: 
0.85-0.99) and 0.97 (95% CI 0.96-0.98) vs. 0.99 
(95% CI 0.77-1.0), respectively44.
Our study has some limitations. First, most of 
the studies did not report the clinical data, patient 
characteristics, contact history, or the time interval 
between the onset of symptoms and sample collec-
tion. Second, several tests have been studied with 
a limited number of samples, and only 61.5% of 
tests included more than 100 samples. Third, all 
the studies included adults or mixed age group pa-
tients, and there were no studies that focused only 
on children. Fourth, we could not assess the over-
all diagnostic performance of the Accula POCT, 
which is a combination of RT-PCR and lateral flow 
immunoassay, due to limited number of clinical 
studies. Fifth, most of the studies were conducted 
in the USA. Further studies are required to ensure 
the applicability of the results of studies of POCTs 
conducted in the USA, in terms of the FDA-EUA 
status, to other countries.
Conclusions
The currently available POCTs approved in 
the USA for study in terms of an FDA-EUA are 
highly accurate for the diagnosis of SARS-CoV-2 
infection. Nevertheless, the findings of our study 
require further large-scale, high-quality clinical 
studies to draw a firm conclusion.
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